Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

114
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
114
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

113
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
113

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

WebCat: the library catalogue on the world wide web.

Annals of the Royal College of Surgeons of England·2000
Same author

Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.

Cancer research·2000
Same author

Importance of phenylalanine 107 in agonist recognition by the 5-hydroxytryptamine(3A) receptor.

Molecular pharmacology·2000
Same author

Practical application of ergonomic settings of typical computerised workstations.

International journal of occupational safety and ergonomics : JOSE·2000
Same author

Structural basis of DOTMA for its high intravenous transfection activity in mouse.

Gene therapy·2000
Same author

The RIP-like kinase, RIP3, induces apoptosis and NF-kappaB nuclear translocation and localizes to mitochondria.

FEBS letters·2000

Related Experiment Video

Updated: Apr 7, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.7K

Programmed Hydrolysis in Designing Paclitaxel Prodrug for Nanocarrier Assembly.

Q Fu1, Y Wang1, Y Ma2

  • 1School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.

Scientific Reports
|July 14, 2015
PubMed
Summary

This study introduces a novel paclitaxel (PTX) prodrug conjugated to vitamin E (VE) via a disulfide bond. This nanocarrier delivery system enhances anticancer activity by utilizing tumor microenvironment reduction to promote drug release and efficacy.

More Related Videos

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes
09:47

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Published on: February 19, 2016

10.2K
A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
09:57

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

9.4K

Related Experiment Videos

Last Updated: Apr 7, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.7K
Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes
09:47

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Published on: February 19, 2016

10.2K
A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
09:57

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

9.4K

Area of Science:

  • Nanotechnology
  • Drug Delivery
  • Oncology

Background:

  • Prodrugs require hydrolysis for therapeutic efficacy.
  • Steric hindrance impedes prodrug hydrolysis, while polarity enhances it.
  • Nanocarriers improve in vivo drug effectiveness and efficiency.

Purpose of the Study:

  • To develop a novel paclitaxel (PTX) prodrug conjugated to vitamin E (VE) via a disulfide bridge (PTX-S-S-VE).
  • To enhance PTX hydrolysis and anticancer activity through nanocarrier delivery and tumor microenvironment-responsive cleavage.
  • To investigate the in vitro and in vivo performance of the PTX-S-S-VE conjugate encapsulated in nanoemulsions.

Main Methods:

  • Synthesis of PTX-S-S-VE conjugate.
  • Encapsulation of the conjugate in VE/VE2-PEG2000/water nanoemulsions.
  • In vitro hydrolysis and cytotoxicity assays.
  • In vivo anticancer activity evaluation in KB-3-1 cell line tumor xenografts.

Main Results:

  • PTX-S-S-VE demonstrated enhanced hydrolysis and increased cytotoxicity in vitro.
  • Nanoemulsions exhibited favorable hydrophobic interactions and long blood circulation.
  • Glutathione in the tumor microenvironment cleaved the disulfide bond, promoting PTX release.
  • Significant reduction in tumor size was observed after the 4th injection in vivo.

Conclusions:

  • The PTX-S-S-VE conjugate delivered via nanoemulsions represents a promising strategy for improving anticancer prodrug efficacy.
  • Exploiting the tumor microenvironment's reducing potential offers a novel approach to enhance prodrug activation.
  • This reduction-triggered unshielding mechanism effectively overcomes steric hindrance and promotes hydrolysis for increased in vivo anticancer activity.